Reviva Pharmaceuticals Holdings Inc (RVPH) concluded trading on Thursday at a closing price of $0.36, with 21.28 million shares of worth about $7.66 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -73.28% during that period and on June 26, 2025 the price saw a loss of about -53.12%. Currently the company’s common shares owned by public are about 46.74M shares, out of which, 41.78M shares are available for trading.
Stock saw a price change of -46.88% in past 5 days and over the past one month there was a price change of -67.45%. Year-to-date (YTD), RVPH shares are showing a performance of -72.03% which decreased to -80.22% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.49 but also hit the highest price of $4.28 during that period. The average intraday trading volume for Reviva Pharmaceuticals Holdings Inc shares is 686.52K. The stock is currently trading -53.68% below its 20-day simple moving average (SMA20), while that difference is down -56.91% for SMA50 and it goes to -71.54% lower than SMA200.
Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) currently have 46.74M outstanding shares and institutions hold larger chunk of about 21.16% of that.
The stock has a current market capitalization of $17.19M and its 3Y-monthly beta is at 0.08. It has posted earnings per share of -$0.79 in the same period. It has Quick Ratio of 0.54. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RVPH, volatility over the week remained 19.29% while standing at 12.19% over the month.
Stock’s fiscal year EPS is expected to rise by 35.60% while it is estimated to decrease by -12.78% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH MKM on September 20, 2023 offering a Buy rating for the stock and assigned a target price of $12 to it. Coverage by The Benchmark Company stated Reviva Pharmaceuticals Holdings Inc (RVPH) stock as a Speculative buy in their note to investors on June 08, 2023, suggesting a price target of $17 for the stock.
